Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: An Eastern Cooperative Oncology Group (ECOG) study

Leukemia Research

Volumn 27, Issue 12, 2003, Pages 1085-1090

  Cherry, Athena M ^a   Brockman, Stephanie R ^b   Paternoster, Sarah F ^b   Hicks, Gary A ^b   Neuberg, Donna ^c   Higgins, Rodney R ^d   Bennett, John M ^e   Greenberg, Peter L ^a,f   Miller, Kenneth ^g   Tallman, Martin S ^h   Rowe, Jacob ⁱ   Dewald, Gordon W ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ABBOTT NORTHWESTERN HOSPITAL   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Chromosome; Cytogenetics; FISH; Hematology; Myelodysplastic syndrome

Indexed keywords

ARTICLE; BONE MARROW BIOPSY; CHROMOSOME 11; CHROMOSOME 20; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; INTERPHASE; METAPHASE; MOLECULAR PROBE; MYELODYSPLASTIC SYNDROME; ONCOLOGY; PRIORITY JOURNAL; Y CHROMOSOME;

EID: 0042563155     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00104-8     Document Type: Article

References (27)

1. Aul C., Gattermann N., Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk. Lymphoma. 16:1995;247-262.
2. Vallespi T., Imbert M., Mecucci C., Preudhomme C., Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica. 83:1998;258-275.
3. Heim S, Mitelman F. Myelodysplastic syndromes. In: Cancer cytogenetics. 2nd ed. New York: Wiley; 1995. p. 141-65.
4. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G.et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088.
5. Mufti G.J. Chromosomal deletions in the myelodysplastic syndrome. Leuk. Res. 16:1992;35-41.
6. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E.et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system. A report on 408 cases. Leukemia. 7:1993;1315-1323.
7. Fenaux P., Morel P., Lai J.L. Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 33:1996;127-138.
8. Rigolin G.M., Cuneo A., Roberti M.G., Bardi A., Bigoni R., Piva N.et al. Exposure to myelotoxic agents and myelodysplasia. Case-control study and correlation with clinicobiologic findings. Br. J. Haematol. 103:1998;189-197.
9. Mauritzson N., Johansson B., Albin M., Billstrom R., Ahlgren T., Mikoczy Z.et al. A single-center population based consecutive series of 1500 cytogenetically investigated adult hematological malignancies. Karyotype features in relation to morphology. Eur. J. Haematol. 62:1999;95-102.
10. Sole F., Espinet B., Sanz G.F., Cevera J., Calasanz M.J., Luno E.et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndrome. Br. J. Haematol. 108:2000;346-356.
11. West R.R., Stafford A., White D., Bowen D.T., Padua R.A. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood. 95:2000;2093-2097.
12. Haase D., Fontasch C., Freund M., Wormann B., Bodenstein H., Bartels H.et al. Cytogenetic finding in 179 patients with myelodysplastic syndromes. Ann. Hematol. 70:1995;171-187.
13. Jenkins R.B., Le Beau M.M., Kraker W.J., Borell T.J., Stalboerger P.G., Davis E.M.et al. Fluorescence in situ hybridization. A sensitive method for trisomy 8 detection in bone marrow specimens. Blood. 79:1992;3307-3315.
14. Brizard F., Brizard A., Guilhot F., Tanzer J., Berger R. Detection of monosomy 7 and trisomies 8 and 11 in myelodysplastic disorders by interphase fluorescent in situ hybridization. Comparison with acute nonlymphocytic leukemias. Leukemia. 8:1994;1005-1011.
15. Flactif M., Lai J.L., Preudhomme C., Fenaux P. Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes. Leukemia. 8:1994;1012-1018.
16. Arif M., Tanaka K., Damodaran C., Asou H., Kyo T., Dohy H.et al. Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization. Leuk. Res. 20:1996;709-716.
17. Cuneo A., Bigoni R., Roberti M.G., Bardi A., Rigolin G.M., Piva N.et al. Detection and monitoring of trisomy 8 by fluorescence in situ hybridization in acute myeloid leukemia. A multicentric study. Haematologica. 83:1998;21-26.
18. Wyandt H.E., Chinnappan D., Ioannidou S., Salama M., O'Hara C. Fluorescence in situ hybridization to assess aneuploidy for chromosomes 7 and 8 in hematologic disorders. Cancer Genet. Cytogenet. 102:1998;114-124.
19. Jakovleva K., Ogard I., Arvidsson I., Jacobsson B., Swolin B., Hast R. Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significance. Leuk. Res. 25:2001;197-203.
20. Rigolin G.M., Bigoni R., Milani R., Cavazzini F., Roberti M.G., Bardi A.et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia. 15:2001;1841-1847.
21. Ketterling R.P., Wyatt W.A., Van Wier S.A., Law M., Hodnefield J.M., Hanson C.A.et al. Primary myelodysplastic syndrome with normal cytogenetics. Utility of 'FISH panel testing' and M-FISH. Leuk. Res. 26:2002;235-240.
22. Romeo M., de Lourdes Chauffaille M., Silva M.R.R., Bahia D.M.M., Kerbauy J. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk. Res. 26:2002;993-996.
23. Bennett J.M., Young M.S., Liesveld J.L., Paietta E., Miller K.B., Lazarus H.M.et al. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML). An Eastern Cooperative Oncology Group Study. Am. J. Hematol. 66:2001;23-27.
24. Mitelman F, editor. Neoplasia. In: ISCN. An international system for human cytogenetic nomenclature. Basel: S. Karger; 1995. p. 78.
25. Kibbelaar R.E., Mulder J.W.R., Dreef E.J., van Kamp H., Fibbe W.E., Wessels J.W.et al. Detection of monosomy 7 and trisomy 8 in myeloid neoplasia. A comparison of banding and fluorescence in situ hybridization. Blood. 82:1993;904-913.
26. Wilkens L., Burkhardt D., Tchinda J., Busche G., Werner M., Nolte M.et al. Cytogenetic aberrations in myelodysplastic syndrome detected by comparative genomic hybridization and fluorescence in situ hybridization. Diagn. Mol. Pathol. 8:1999;47-53.
27. Mohr B., Bornhauser M., Thiede C., Schakel U., Schaich M., Illmer T.et al. Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 14:2000;1031-1038.